Folia Health Raises $10.5M Series A to Advance Patient-Driven Real-World Evidence Platform
核心洞察
Folia Health (搜索) secured $10.5 million in Series A funding led by S3 Ventures (搜索) to expand its patient-driven platform that transforms home-reported outcomes into clinical-grade real-world evidence.
The Boston-based company's platform enables patients with chronic and rare diseases to track symptoms and treatments while maintaining full control over their data through explicit consent protocols and revenue-sharing programs.
Folia's approach has generated research-grade data across multiple conditions including lupus (搜索), sickle cell disease (搜索), and cystic fibrosis (搜索), informing FDA discussions and treatment guidelines.
Folia Health (搜索), a Boston-based patient-driven health company, announced the completion of a $10.5 million Series A funding round led by S3 Ventures (搜索), with participation from longtime partner Crosslink Capital (搜索) and specialist fund Create Health Ventures (搜索). The investment will enable the company to expand its mission of transforming patient experiences into structured data insights for research and personalized care.
Patient-Controlled Data Platform
Folia Health (搜索) has pioneered home-reported outcomes (HROs), creating a platform that enables individuals to track symptoms, treatments, and outcomes while maintaining unprecedented control over their data. The company's commitment to transparency requires explicit consent for any external research use, provides detailed Participant Reports showing how data is utilized, and allows participants to withdraw at any time.
"This funding is an affirmation of our fierce dedication to making patient-focused healthcare a reality," said Nell Meosky Luo, founder and CEO of Folia Health (搜索). "People live in their bodies 24/7 — they notice patterns, track what works, spot when something's off. The knowledge held by each of our participants fills crucial knowledge gaps in traditional health data, which focuses on what happens when you're at the clinic."
The platform also features a revenue-sharing program called Data Dividends, which compensates participants for their contributions to research studies.
Clinical Impact and Research Applications
Folia's approach generates high-quality, longitudinal real-world evidence that has informed FDA discussions and treatment guidelines. The platform has established partnerships with leading life science companies and generated research-grade data across conditions including lupus (搜索), sickle cell disease (搜索), eczema (搜索), and paroxysmal nocturnal hemoglobinuria (搜索) (PNH).
Current research initiatives include active studies across multiple rare kidney diseases in partnership with a major life science organization, a national study on the impact of Trikafta in cystic fibrosis (搜索), the first app-based remote study capturing daily experiences of people with IgA nephropathy (搜索), and longitudinal research in sickle cell disease (搜索) addressing healthcare disparities and pain management challenges.
AI-Ready Data Foundation
The company positions its patient-generated data as essential for the development of AI tools in healthcare. Dan Toffling, co-founder and CTO of Folia Health (搜索), emphasized the importance of comprehensive datasets for AI applications: "What gets lost in the excitement over the power of AI is the fact that these new technologies require the right data to give us insights that are meaningful and useful. Right now we're dependent on incomplete and skewed datasets, typically information that's collected a few days out of the year during brief interactions with clinicians."
Community Insights Initiative
The funding announcement follows Folia's recent launch of Mosaic, a community insights research initiative that enables participants to ask questions and receive answers based on aggregated data from others with similar conditions. The program is currently active for users with eczema (搜索) and PNH, with plans to expand to lupus (搜索) and sickle cell disease (搜索) in 2026.
Investor Perspective
Brian R. Smith, Managing Director at S3 Ventures (搜索), highlighted the company's established track record: "Folia is a validated research platform redefining how we understand chronic and rare diseases. Nearly a decade of peer-reviewed research positions Folia as the gold standard for patient-driven real-world evidence, and we are thrilled to support their growth across new conditions and partnerships."
Founded in 2016 by family caregivers, Folia Health (搜索) has built its platform on the principle that patient and caregiver knowledge represents the missing piece needed for precise, individualized care and high-impact research. The company maintains high standards of data privacy and patient autonomy while bridging the gap between patients, clinicians, and researchers.